Fortress Biotech, Inc.

As of August 11, 2025, Fortress Biotech, Inc. shows a bullish technical trend driven by moving averages and MACD indicators, despite a bearish monthly RSI, having significantly outperformed the S&P 500 recently while underperforming over the longer term.

Fortress Biotech, Inc. is considered overvalued and risky due to negative financial metrics, including a Price to Book Value of 2.66, an alarming -482.55% Return on Equity, and a troubling 5-year return of -95.03%, despite a strong 85.42% return over the past year.

As of May 10, 2016, Fortress Biotech, Inc. is considered overvalued and risky due to negative performance metrics, including a P/E ratio of -0.5040, a year-to-date decline of 15.56%, and poor comparisons to peers in the industry.

As of June 17, 2025, the market trend is neutral with mixed signals, showing a shift from mildly bullish to sideways, as indicated by varying performances in MACD, moving averages, Bollinger Bands, KST, and Dow Theory.

As of March 2022, Fortress Biotech, Inc.'s management team includes Dr. Lindsay Rosenwald (Executive Chairman, CEO), Dr. Eric Rowinsky (Co-Vice Chairman), Mr. Michael Weiss (Executive Vice Chairman), and several independent directors. They are responsible for the company's strategic direction and operations.

Fortress Biotech, Inc. is a micro-cap biopharmaceutical company focused on acquiring, developing, and commercializing novel pharmaceutical and biotechnology products. As of March 2025, it reported net sales of $13 million and a net loss of $25 million, with a market cap of $54.11 million.

As of Jun 18, Fortress Biotech, Inc. has a market capitalization of 54.11 million and reported net sales of 57.79 million, with a net loss of 106.52 million over the latest four quarters. Shareholder's funds are 22.74 million, and total assets amount to 144.22 million.